Biomx Inc (PHGE_u)

NYSE
5.520
-0.600(-9.81%)
  • Volume:
    100
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    5.520 - 5.520

PHGE_u Overview

Prev. Close
6.12
Day's Range
5.52-5.52
Revenue
-
Open
5.52
52 wk Range
5.52-11.164
EPS
0.03
Volume
100
Market Cap
64.23M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
201
P/E Ratio
372.68
Beta
-
1-Year Change
-18.46%
Shares Outstanding
8,750,000
Next Earnings Date
-
What is your sentiment on Biomx Inc?
or
Vote to see community's results!

Biomx Inc News

Technical Summary

Type
Daily
Weekly
Monthly
Moving AveragesStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong Sell

Biomx Inc Company Profile

Biomx Inc Company Profile

Employees
101

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company’s lead product candidate BX001, which is in Phase II that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type. Its products under development include BX003 to treat acne-prone skin, IBD, and PSC; BX004, a therapeutic phage product candidate for chronic respiratory infections caused by pseudomonas aeruginosa; and BX005, a topical phage product candidate for staphylococcus aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis, as well as CRC program targets strains of bacteria found in CRC tumors. The company has license agreement with Keio University and JSR Corporation to bacterial targets that are related to IBD and the phage to eradicate these bacterial targets. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.